SEPN Septerna, Inc.
Septerna, Inc. (SEPN) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $1.5M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Labrucherie Gil M 3 fills | Chief Financial Officer | Sell 10b5-1 | 20,000 | $41.62 | $832.4K | 24,185 −45.3% of holding | |
| Finer Jeffrey 5 fills | Chief Executive Officer | Sell 10b5-1 | 18,500 | $43.62 | $807.0K | 846,809 −2.1% of holding | |
| Ezekowitz Alan 7 fills | Director | Sell 10b5-1 | 81,820 | $48.09 | $3.9M | 110,481 −42.5% of holding | |
| Bhatt Elizabeth 2 fills | President and COO | Sell 10b5-1 | 4,000 | $37.41 | $149.6K | 177,115 −2.2% of holding | |
| Long Daniel D. | SVP, Drug Discovery | Sell 10b5-1 | 3,333 | $37.83 | $126.1K | 96,412 −3.3% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.